Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31437865 | 0.87 | ENPP2 (0.59) | L3MBTL1ALDH1A1MAPTPOLBHPGD | |
| SCHEMBL29953019 | 0.85 | CSNK2A1 (0.44) | L3MBTL1ALDH1A1MAPTPOLBHPGD | |
| SCHEMBL4881084 | 0.85 | CSNK2A1 (0.44) | L3MBTL1ALDH1A1MAPTPOLBHPGD | |
| SCHEMBL1516637 | 0.85 | KDR (0.50) | L3MBTL1ALDH1A1MAPTPOLBHPGD | |
| SCHEMBL29956963 | 0.84 | ENPP2 (0.43) | L3MBTL1ALDH1A1MAPTPOLBHPGD | |
| SCHEMBL430117 | 0.82 | KDR (0.51) | L3MBTL1ALDH1A1MAPTPOLBHPGD | |
| SCHEMBL29956646 | 0.81 | ENPP2 (0.46) | ALDH1A1MAPTPOLBHPGDNPSR1 | |
| SCHEMBL2854999 | 0.81 | ENPP2 (0.46) | ALDH1A1MAPTPOLBHPGDNPSR1 | |
| SCHEMBL2551648 | 0.81 | UTS2R (0.46) | ALDH1A1MAPTMEN1MAPK1KMT2A | |
| SCHEMBL31469079 | 0.81 | ALDH1A1 (0.50) | L3MBTL1ALDH1A1MAPTPOLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11560373-B2 | Compounds and their use as PDE4 activators | MIRONID LIMITED (GB) | 2023-01-24 | — | — | US | disclosed |
| EP-3774780-B1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | MIRONID LTD (GB) | 2022-11-23 | — | — | EP | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3774780-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | Mironid Limited (GB) | 2021-02-17 | — | — | EP | disclosed |
| US-20210032231-A1 | Compounds and Their Use as PDE4 Activators | MIRONID LIMITED (GB) | 2021-02-04 | — | — | US | disclosed |
| WO-2019193342-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | MIRONID LIMITED (GB) | 2019-10-10 | — | — | WO | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| EP-2558577-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011127933-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2011-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210032231-A1 | Compounds and Their Use as PDE4 Activators | PDE4A, PDE4B, PDE4C | L3MBTL1 4149/4885ALDH1A1 1009/4885MAPT 4560/4885 |
| US-11560373-B2 | Compounds and their use as PDE4 activators | PDE4A, PDE4B, PDE4C | L3MBTL1 4149/4885ALDH1A1 1009/4885MAPT 4560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.